A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Clinical trial NCT06581406 · RECRUITING
Trial details
- NCT number
- NCT06581406
- Sponsor
- Replimune, Inc.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-17
- Primary completion
- 2030-01-01
- Enrollment
- 280
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.